Abstract
Background Statins are becoming more widely used among women of reproductive age; however, nationwide data on statin use across pregnancy is scarce. We therefore aimed to describe the drug utilization patterns for statins and other lipid-modifying agents (LMAs) before, during, and after pregnancy, for all pregnancies in Norway from 2005 to 2018.
Methods We linked individual-level data from four nationwide electronic health care registries in Norway and characterized the prescription fills of statins and other LMAs across pregnancy. We also examined trends in pregnancy-related LMA use, and characterized women using statins and other LMAs on parameters of health status and co-morbidity.
Results In total 822 071 pregnancies for 503 723 women were included. The number of statin prescription fills decreased rapidly during first trimester and returned to pre-pregnancy levels about one year postpartum. Pregnancy-related statin use increased from 2005 (approx. 0.11 % of all pregnancies) to 2018 (approx. 0.29 % of all pregnancies); however, in total, few statin prescriptions were filled within any trimester of pregnancy (n = 331, 0.04 % of all pregnancies). Statin use was more common in women with higher age, higher weight, smoking, and comorbidities such as hypertension and diabetes mellitus; also, statin users often had co-medication pertinent to these conditions.
Conclusions Although statins and other LMAs were increasingly being used around the time of pregnancy among women in Norway, drug use was mostly discontinued during first trimester. Our results suggest that pregnancy-related statin use should be monitored, and that drug safety analyses for maternal and offspring health outcomes are needed.
Competing Interest Statement
Dr. Christensen has received research grants and/or personal fees from Mills DA, none of which is related to the content of this manuscript. Dr. Holven has received research grants and/or personal fees from Tine DA, Mills DA, Olympic Seafood, Amgen, and Sanofi, none of which are related to the content of this manuscript. Dr. Bogsrud has received personal fees from Amgen, and Sanofi, none of which are related to the content of this manuscript. The other authors have no financial relationships relevant to disclose.
Funding Statement
This work was funded by the University of Oslo (Oslo, Norway), the National Advisory Unit on FH at OUH (Oslo, Norway), the Throne-Holst Foundation for Nutrition Research (Oslo), and the South-Eastern Regional Health Authority (Oslo, Norway). Data access fees were covered by the PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo (Oslo, Norway).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was approved by the Regional Committee for Research Ethics in South-Eastern Norway (approval number 2018/140/REK South-East) and by the Data Protection Officer at the University of Oslo (approval number 58033).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclaimers: None.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- ATC
- The World Health Organization–s Anatomical Therapeutic Chemical Classification System
- DDDs
- defined daily doses
- ICD-10
- The International Classification of Diseases, version 10
- ICPC-2
- The International Classification of Primary Care-2
- KUHR
- The Norway Control and Payment of Health Reimbursement Database
- LMA
- lipid-modifying agents
- MBRN
- The Medical Birth Registry of Norway
- NorPD
- The Norwegian Prescription Registry
- NPR
- The Norwegian Patient Registry
